• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [23369 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2014     National Evidence-based Healthcare Collaborating Agency (NECA) [Outcomes research for complications of inhaled bronchodilators/corticosteroids]
2014     Health Quality Ontario (HQO) Physiotherapy after knee arthroscopy: a rapid review
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Compression therapy in diabetic foot ulcer management: a review of clinical effectiveness, cost-effectiveness and guidelines
2014     NIHR Horizon Scanning Centre (NIHR HSC) Obinutuzumab in combination with CHOP chemotherapy for CD20-positive diffuse large B-cell lymphoma – first line
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Flushing intravenous tubing post administration of medications: clinical evidence and guidelines
2014     National Evidence-based Healthcare Collaborating Agency (NECA) [Indirect comparison methodology research for health technology assessment: Comparison of drug treatment effect in adult attention deficit hyperactivity disorder using a common comparator]
2014     Health Quality Ontario (HQO) Preoperative shower or bath with antiseptics before knee arthroscopy: a rapid review
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Initiatives to optimize the utilization of laboratory tests
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Corneal cross-linking with riboflavin for keratoconus: update of clinical and cost-effectiveness
2014     NIHR Horizon Scanning Centre (NIHR HSC) Obinutuzumab in combination with bendamustine for rituximab-refractory indolent non-Hodgkin's lymphoma – second line
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Paracentesis for the removal of peritoneal fluid: guidelines
2014     National Evidence-based Healthcare Collaborating Agency (NECA) [Current status and outcomes analysis of radiosurgery for spinal tumours]
2014     Health Quality Ontario (HQO) Peripheral nerve blocks for post-operative pain relief after arthroscopic knee ligament reconstruction: a rapid review
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Narcotics, benzodiazepines, stimulants, and gabapentin: policies, initiatives, and practices across Canada, 2014
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Ferumoxytol versus other intravenous iron therapies for anemia: a review of the clinical and cost-effectiveness and guidelines
2014     NIHR Horizon Scanning Centre (NIHR HSC) Ixazomib citrate for relapsed and/or refractory multiple myeloma
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Positron emission tomography in neurology and cardiology: a review of guidelines and recommendations
2014     National Evidence-based Healthcare Collaborating Agency (NECA) [New health technology assessment guideline development]
2014     Health Quality Ontario (HQO) Bracing after knee arthroscopy: a rapid review
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) HbA1c testing frequency: a review of the clinical evidence and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Antibacterial sutures for wound closure after surgery: a review of clinical and cost-effectiveness and guidelines for use
2014     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Out of hours emergency coronary angiography and/or coronary angioplasty and stenting
2014     NIHR Horizon Scanning Centre (NIHR HSC) HA-irinotectan for metastatic colorectal cancer – second and third line
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Buprenorphine/naloxone (Suboxone) film versus buprenorphine/naloxone tablets for the treatment of opioid addiction: comparative safety
2014     National Evidence-based Healthcare Collaborating Agency (NECA) Bayesian meta-analysis method
2014     Health Quality Ontario (HQO) Intra-articular analgesia after knee arthroscopy: a rapid review
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Gabapentin for adults with neuropathic pain: a review of the clinical evidence and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Non-contact thermometers for detecting fever: a review of clinical effectiveness
2014     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Final protocol to guide the assessment of magnetic resonance imaging of liver lesions
2014     NIHR Health Technology Assessment programme The clinical effectiveness and cost-effectiveness of second-eye cataract surgery: a systematic review and economic evaluation
2014     NIHR Horizon Scanning Centre (NIHR HSC) Inotuzumab ozogamicin for acute lymphoblastic leukaemia – second or subsequent line
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Oncotype DX in women and men with ER-positive HER2-negative early stage breast cancer Who are lymph node-positive: a review of clinical effectiveness and guidelines
2014     National Evidence-based Healthcare Collaborating Agency (NECA) [Clinical effectiveness and safety of robotic surgery]
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) The use of the electromotive drug administration system in patients with overactive bladder: a review of the clinical effectiveness, safety, and cost-effectiveness
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Mass thermography screening for infection and prevention: a review of the clinical effectiveness
2014     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Consultation protocol to guide the assessment of foot and ankle services by podiatric surgeons
2014     NIHR Horizon Scanning Centre (NIHR HSC) Idelalisib and ofatumumab for relapsed chronic lymphocytic leukaemia
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Compressible non-articulating disc prostheses in adult patients with degenerative disc disease: clinical effectiveness, safety, cost-effectiveness, and guidelines
2014     National Evidence-based Healthcare Collaborating Agency (NECA) [Decision Making Process for Safety Issues in Health Services and Technologies]
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Botulinum toxin A for myofascial pain syndrome: a review of the clinical effectiveness
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Long-acting beta2-agonists for chronic obstructive pulmonary disease: safety and harms
2014     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Local anaesthetic (LA) nerve blockade for post-surgical analgesia
2014     NIHR Horizon Scanning Centre (NIHR HSC) Etirinotecan pegol for metastatic breast cancer - second or subsequent line
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Smart infusion pump use in hospitalized patients: clinical safety and guidelines
2014     National Evidence-based Healthcare Collaborating Agency (NECA) [A study on the system and execution model for health technology reassessment]
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) The use of the electromotive drug administration system in patients with superficial bladder cancer: a review of the clinical effectiveness, safety, and cost-effectiveness
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Transmission of infectious agents from magazines, books, and toys in healthcare settings: clinical evidence and guidelines
2014     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Vagus nerve stimulation therapy
2014     NIHR Horizon Scanning Centre (NIHR HSC) Cediranib for ovarian cancer – second line
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Intranasal versus intravenous administration of anxiolytic or analgesic medications: comparative clinical effectiveness
2014     National Evidence-based Healthcare Collaborating Agency (NECA) [Study on the introduction of horizon scanning system for emerging health technology]
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Hydroxyethyl starch use for patients with postpartum hemorrhage: a review of clinical effectiveness, safety, and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Implementation of extracorporeal membrane oxygenation: clinical evidence
2014     NIHR Health Technology Assessment programme KRAS mutation testing of tumours in adults with metastatic colorectal cancer: a systematic review and cost-effectiveness analysis
2014     NIHR Horizon Scanning Centre (NIHR HSC) Alisertib for relapsed or refractory peripheral T-cell lymphoma – second and subsequent line
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Intensivist response time to a closed intensive care unit: patient benefits and harms and guidelines
2014     National Evidence-based Healthcare Collaborating Agency (NECA) [The mortality rate and medical costs identified by a national health examination analysis]
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Debridement procedures for managing diabetic foot ulcers: a review of clinical effectiveness, cost-effectiveness, and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Screening tools to identify adults with cognitive impairment associated with dementia: diagnostic accuracy
2014     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Insertion of subcutaneous electrode for the purpose of use with an implantable cardioverter defibrillator (ICD)
2014     NIHR Horizon Scanning Centre (NIHR HSC) Cholic acid (Orphacol) for inborn errors of primary bile acid synthesis – first line
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) TECNIS® or Acrysof® soft intraocular lenses for patients undergoing cataract surgery: benefits and harms, clinical effectiveness, cost-effectiveness, and guidelines
2014     National Evidence-based Healthcare Collaborating Agency (NECA) [Priority setting of clinical preventive services for benefits extension]
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Nabilone for non-chemotherapy-associated nausea and weight loss due to medical conditions: a review of the clinical effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Treatment strategies for patients with renal colic: a review of the comparative clinical and cost-effectiveness
2014     NIHR Horizon Scanning Centre (NIHR HSC) Migalastat for Fabry disease: update
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Wireless device use and patient monitoring equipment in any healthcare delivery setting: a review of safety and guidelines
2014     National Evidence-based Healthcare Collaborating Agency (NECA) [Cost-effectiveness of conventional cytology and HPV DNA testing for cervical cancer screening in South Korea]
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Drug therapy for chronic thromboembolic pulmonary hypertension: a review of the comparative clinical effectiveness
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Treatments for constipation: a review of systematic reviews
2014     NIHR Horizon Scanning Centre (NIHR HSC) Denosumab for glucocorticoid-induced osteoporosis
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Montelukast for sleep apnea: a review of the clinical effectiveness, cost effectiveness, and guidelines
2014     National Evidence-based Healthcare Collaborating Agency (NECA) [Diagnostic usefulness of brain FDG-PET for Alzheimer's dementia]
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Infection prevention and control procedures for carbapenemase-producing Enterobacteriaceae: clinical effectiveness and guidelines
2014     NIHR Horizon Scanning Centre (NIHR HSC) Perampanel for adjuvant treatment of primary generalised tonic-clonic seizures
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Nicotine replacement therapy for smoking cessation or reduction: a review of the clinical evidence
2014     National Evidence-based Healthcare Collaborating Agency (NECA) [Comparative effectiveness of medication therapies in the rheumatoid arthritis patients]
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Acyclovir versus valacyclovir for herpes virus in children and pregnant women: a review of the clinical evidence and guidelines
2014     NIHR Horizon Scanning Centre (NIHR HSC) Daclatasvir and sofosbuvir (Sovaldi) with and without ribavirin for chronic hepatitis C infection
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Dexmedetomidine for sedation of patients in the ICU or PICU: review of clinical effectiveness and safety
2014     National Evidence-based Healthcare Collaborating Agency (NECA) [Health Technology Assessment on diagnostic testing: Cardiac MRI and MRSA genetic testing (Real-time polymerase chain reaction)]
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Obstetric, neonatal, and child outcomes for women with previous bariatric surgery: a review of the clinical evidence
2014     Institute for Clinical and Economic Review (ICER) Appropriate imaging for breast cancer screening in special populations
2014     NIHR Horizon Scanning Centre (NIHR HSC) Tofacitinib for moderate to severe active ulcerative colitis
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Saxagliptin (Onglyza - Bristol-Myers Squibb/AstraZeneca Canada Inc.) indication: type 2 diabetes mellitus
2014     Agency for Healthcare Research and Quality (AHRQ) Imaging techniques for treatment evaluation for metastatic breast cancer
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Essential oil products for disinfection: clinical effectiveness, cost-effectiveness, and guidelines
2014     Institute for Clinical and Economic Review (ICER) Proton beam therapy
2014     Scottish Health Technologies Group (SHTG) Transcatheter aortic valve implantation (TAVI) for severe symptomatic aortic stenosis in adults at high surgical risk
2014     NIHR Horizon Scanning Centre (NIHR HSC) Ixazomib in combination with oral dexamethasone for relapsed or refractory systemic light chain (AL) amyloidosis
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical review report. Saxagliptin (Onglyza - Bristol-Myers Squibb/AstraZeneca Canada Inc.) indication: type 2 diabetes mellitus
2014     Agency for Healthcare Research and Quality (AHRQ) The effectiveness and risks of long-term opioid treatment of chronic pain
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Pharmacoeconomic review report. Sofosbuvir (Sovaldi — Gilead Sciences Canada, Inc.) indication: chronic hepatitis C infection
2014     Scottish Health Technologies Group (SHTG) Transcatheter aortic valve implantation (TAVI) for severe symptomatic aortic stenosis in adults who are not eligible for surgery
2014     NIHR Horizon Scanning Centre (NIHR HSC) Levosimendan (Leximda) for severe acute decompensated chronic heart failure – second line
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Pharmacoeconomic review report. Saxagliptin (Onglyza - Bristol-Myers Squibb/AstraZeneca Canada Inc.) indication: type 2 diabetes mellitus
2014     Agency for Healthcare Research and Quality (AHRQ) Imaging tests for the diagnosis and staging of pancreatic adenocarcinoma
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical review report. Sofosbuvir (Sovaldi — Gilead Sciences Canada, Inc.) indication: chronic hepatitis C infection
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Ulipristal Acetate (Fibristal - Actavis Specialty Pharmaceuticals Co.) indication: uterine fibroids
2014     Agency for Healthcare Research and Quality (AHRQ) Chronic urinary retention: comparative effectiveness and harms of treatments.